ADC Therapeutics (ADCT) Payables (2019 - 2023)
Historic Payables for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $9.0 million.
- ADC Therapeutics' Payables fell 2268.54% to $9.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.0 million, marking a year-over-year decrease of 2268.54%. This contributed to the annual value of $12.4 million for FY2022, which is N/A changed from last year.
- Latest data reveals that ADC Therapeutics reported Payables of $9.0 million as of Q3 2023, which was down 2268.54% from $11.7 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Payables ranged from a high of $16.5 million in Q1 2022 and a low of $3329.0 during Q4 2019
- Moreover, its 5-year median value for Payables was $11.5 million (2021), whereas its average is $8.6 million.
- In the last 5 years, ADC Therapeutics' Payables skyrocketed by 21515673.09% in 2021 and then crashed by 4715.86% in 2023.
- Quarter analysis of 5 years shows ADC Therapeutics' Payables stood at $3329.0 in 2019, then soared by 84.62% to $6146.0 in 2020, then skyrocketed by 96.55% to $12080.0 in 2021, then soared by 102143.38% to $12.4 million in 2022, then dropped by 27.32% to $9.0 million in 2023.
- Its Payables was $9.0 million in Q3 2023, compared to $11.7 million in Q2 2023 and $8.7 million in Q1 2023.